Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.

To grow, cancer tumors must hijack the immune system for their needs. One of the main tricks that most tumors use is to ...

REDWOOD CITY, CA, USA I April 14, 2025 I Pheast Therapeutics, a private biotechnology company developing novel therapies to unleash the power of macrophages ...

Pheast Therapeutics has treated the first subject in a multi-centre Phase I trial for the anti-cluster of differentiation 24 (CD24) macrophage checkpoint blocker PHST001, aimed at treating advanced ...

Orthodontic treatments often take years, but a breakthrough discovery could drastically shorten this period. Researchers have uncovered that ATF6, a ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious ...

Thanks to the NIH, researchers like Andrew Ewald have advanced our understanding of what allows a cancer cell from one part ...

Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/r HR MDS) Topline read-out from the Phase II BEXMAB trial confirms earlier positive findings ...

PhD student Kirstin Rollins bests a competitive field of more than 40 graduate students and eight finalists to claim the ...